Abstract:
PURPOSE: A pharmaceutical composition and a health functional food containing methyl caffeate for preventing and treating obesity and lipid related metabolic diseases are provided to suppress adipocyte differentiation. CONSTITUTION: A pharmaceutical composition for preventing and treating obesity and lipid related metabolis diseases contains methyl caffeate as an active ingredient. The methyl caffeate is n-octyl-3,4-dimethyl caffeate. The metabolic diseases are hyperlipidemia, fatty liver, arteriosclerosis, cardiovascular disease, or metabolic disease of combination thereof. The composition is a capsule, tablet, granule, powder, or beverage. A health functional food for preventing and relieving obesity and lipid related metabolic disease contains the metyl caffeate as an active ingredient. The health functional food is a capsule, tablet, granule,powder, or beverage. [Reference numerals] (AA) Control group
Abstract:
PURPOSE: A pharmaceutical composition containing benzylisothiocyanate is provided to suppress differentiation into adipocytes and to prevent and treat obesity and lipid-associated metabolic diseases. CONSTITUTION: A pharmaceutical composition for preventing and treating obesity and lipid-associated metabolic diseases contains benzyl isothiocyanate as an active ingredient. The metabolic diseases are diabetes, hyperlipidemia, fatty liver, artheriosclerosis, hypertension, cardiovascular diseases or combination thereof. The pharmaceutical composition is manufactured in the form of powder, granules, tablets, capsules, suspension, emulsion, syrup, external use, suppository, or sterilized injection solution. A health food for preventing and treating obesity and lipid-associated metabolic diseases contains benzylisothiocyanate as an active ingredient. The health food is a capsule, tablet, granule, powder, or drink.
Abstract:
본 발명은 비만 또는 비만관련질환 여부의 진단 및 치료에 필요한 정보를 제공하기 위하여 피험체로부터 분리된 혈액에서 아르기닌, 타이로신, 피페콜린산, 벤조산, 판토테닌산, 요산, 페닐피루빈산, 페닐아세타마이드, 세로토닌, L-카르니틴, 데카노일카르니틴, 미리스토일카르니틴, 헥사데케노일카르니틴, 리놀레일카르니틴, 바세닐카르니틴, 스테아로일카르니틴, lysoPC(C14:0), lysoPC(C15:0), lysoPC(C16:0), lysoPC(C16:1), lysoPC(C17:0), lysoPC(C17:1), lysoPC(C18:0), lysoPC(C18:1), lysoPC(C18:2), lysoPC(C18:3), lysoPC(C19:0), lysoPC(C20:1), lysoPC(C20:4), lysoPC(C20:5), lysoPE(C18:2), lysoPE(C20:4) 및 PCs에서 선택된 적어도 하나의 마커, 또는 간의 추출물에서 글루코즈, 글리세롤, 타이로신, 발린, 7-케토데옥시콜린산, 판토테닌산, 베타인, L-카르니틴, 3-메틸구타릴카르니틴, 팔미텔라이딘산, 팔미틴산, 리� ��레인산, 올레인산, 스테아린산, 멜리비오즈, lysoPC(C14:0), lysoPC(C16:0), lysoPC(C16:1), lysoPC(C18:0), lysoPC(C18:3), lysoPC(C20:4), lysoPC(C22:6), 및 PCs의 군에서 선택된 적어도 하나의 마커의 농도를 검출하는 방법 및 이를 이용한 비만억제활성을 갖는 식품 내지 약물의 스크리닝방법을 제공한다.
Abstract:
PURPOSE: An anti-diabetic composition containing biochanin A or salt thereof is provided to concentration-dependently increase phosphorylation of AMPK. CONSTITUTION: An anti-diabetic composition contains biochanin A or salt thereof as an active ingredient. A pharmaceutical composition for preventing and treating diabetes contains biochanin A or pharmacologically acceptable salt thereof as an active ingredient. A food composition for preventing and treating diabetes contains biochanin A or sitologically acceptable salt thereof as an active ingredient. Biochanin A or salt thereof is contained in 1-10 wt%.
Abstract:
본 발명은 도미 추출물, 바람직하게 참돔 추출물을 유효성분으로 포함하는 비만, 지방간 또는 대사성 증후군 개선용 약학 조성물 또는 건강기능식품에 관한 것으로, 더욱 상세하게 본 발명에 따르는 도미 추출물, 바람직하게 참돔 추출물은 AMPK의 활성화 및 SREBP-1c 및 FAS(Fatty Acid Synthase) 발현을 억제시켜 지방산 합성을 억제 및 중성지방 합성을 억제한다.
Abstract:
본 발명은 도미 추출물, 바람직하게 참돔 추출물을 유효성분으로 포함하는 비만, 지방간 또는 대사성 증후군 개선용 약학 조성물 또는 건강기능식품에 관한 것으로, 더욱 상세하게 본 발명에 따르는 도미 추출물, 바람직하게 참돔 추출물은 AMPK의 활성화 및 SREBP-1c 및 FAS(Fatty Acid Synthase) 발현을 억제시켜 지방산 합성을 억제 및 중성지방 합성을 억제한다.